NCT06254495

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

A Phase 1, Open-label Study to Evaluate PF-08046044/SGN-35C in Adults With Advanced Malignancies.

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Conditions

• Hodgkin Disease
• Lymphoma, T-Cell, Peripheral
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Large-Cell, Anaplastic

Interventions

Type	Name	Description
DRUG	PF-08046044/SGN-35C	Given into the vein (IV; intravenously)

Timeline

• Start date: 2024-05-28
• Primary completion: 2028-04-18
• Completion: 2029-04-18
• First posted: 2024-02-12
• Last updated: 2026-04-07

Locations

32 sites across 6 countries: United States, Denmark, France, Italy, Spain, United Kingdom

Regulatory

• FDA-regulated drug study